151213-40-0

Basic information

• Product Name: CIS-OCTAHYDROPYRROLO[3,4-B]PYRIDINE
• Synonyms: CIS-OCTAHYDROPYRROLO[3,4-B]PYRIDINE;(R,R)-2,8-DIAZABICYCLO[4,3,0]NONANE;(4aS,7aS)-Octahydro-1H-pyrrolo[3,4-b]pyridine (4aS-cis)-Octahydro-1H-pyrrolo[3,4-b]pyridine;1H-Pyrrolo[3,4-b]pyridine, octahydro-;cis-Octahydro-pyrrolo[3,4-b]pyridine 2HCl;(4aS,7aS)-Octahydro-1H-pyrrolo[3,4-β]pyridine (4aS-cis)-Octahydro-1H-pyrrolo[3,4-β]pyridine;(R,R)-2, 8-Diazabicyclo[4,3,0 ]nonane ,95%;(S,S)-2,8-Diazabicyclo[4,3,0]nonane ,97%
• CAS NO: 151213-40-0
• Molecular Formula: C₇H₁₄N₂
• Molecular Weight: 126.2
• EINECS: 2017-001-1
• Product Categories: pharmacetical;Chiral Reagents;Heterocycles;NULL
• Mol File: 151213-40-0.mol
• Article Data: 30

Chemical Properties

• Boiling Point: 198℃
• Flash Point: 87℃
• Appearance: Light pink oil
• Density: 0.950
• Vapor Pressure: 0.00209mmHg at 25°C
• Refractive Index: n20/D1.515
• Storage Temp.: Refrigerator
• Solubility: Chloroform (Slightly), Methanol (Slightly), Water (Sparingly)
• PKA: 11.11±0.20(Predicted)
• CAS DataBase Reference: CIS-OCTAHYDROPYRROLO[3,4-B]PYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: CIS-OCTAHYDROPYRROLO[3,4-B]PYRIDINE(151213-40-0)
• EPA Substance Registry System: CIS-OCTAHYDROPYRROLO[3,4-B]PYRIDINE(151213-40-0)

Safety Data

• Hazard Codes: Xn
• Statements: 41
• Safety Statements: 26
• RIDADR: NA 1993 / PGIII
• Hazardous Substances Data: 151213-40-0(Hazardous Substances Data)

Usage

InChI:InChI=1/C7H14N2.2ClH/c1-2-6-4-8-5-7(6)9-3-1;;/h6-9H,1-5H2;2*1H/t6-,7+;;/m0../s1

Upstream product

• 1430075-11-8 1-benzyl-4-(3-ethoxycarbonylpropyl)-3-pyrrolidone 
• 1430075-01-6 C₂₄H₃₂N₂O₂ 
• 1430075-04-9 C₂₂H₃₀N₂O 
• 1430075-02-7 (5S,6S)-2-((R)-1-phenyl-ethyl)-8-benzyl-3-oxo-2,8-diazabicyclo[4.3.0]nonane 
• 1430075-03-8 (4aS,7aS)-6-benzyl-1-((R)-1-phenylethyl)octahydro-1H-pyrrolo[3,4-b]pyridine 
• 1430075-05-0 C₂₉H₃₄N₂O₂ 
• 1430075-08-3 C₁₈H₂₆N₂O₂ 
• 1430075-09-4 C₁₉H₂₅NO₅ 
• 151213-39-7 (S,S)-8-benzyl-2,8-diazabicyclo[4.3.0]nonane-D-tartrate 
• 177785-14-7 2-chloromethyl-pyridine-3-carboxylic acid methyl ester 

Downstream Products

• 186826-86-8 moxifloxacin hydrochloride 
• 192927-63-2 1-cyclopropyl-7-([S,S]-2,8-diazabicyclo[4.3.0]non-8-yl)-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid monohydrochloride monohydrate 
• 151213-39-7 (S,S)-8-benzyl-2,8-diazabicyclo[4.3.0]nonane-D-tartrate 
• 151636-46-3 (S,S)-8-benzyl-2,8-diazabicyclo[4.3.0]nonane tartrate salt 
• 721970-35-0 methyl 1-cyclopropyl-6-fluoro-8-methoxy-7-((4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylate 
• 1029364-75-7 1-cyclopropyl-8-ethoxy-6-fluoro-7-((4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-4 oxo-1,4-dihydroquinoline-3-carboxylic acid 
• 721970-36-1 1-cyclopropyl-7-{(S,S)-2,8-diazabicyclo[4.3.0]non-8-yl}-6-fluoro-8-hydroxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid 
• 1029364-77-9 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-1H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-3-quinolinecarboxylic acid 
• 151096-44-5 1-cyclopropyl-6,8-difluoro-7-((4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 
• 128740-61-4 8-chloro-1-cyclopropyl-6-fluoro-7-(octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 
• 151096-09-2 moxifloxacin 
• 1038923-74-8 (S,S)-6-(toluene-4-sulfonyl)-octahydro-pyrrolo[3,4-b]pyridine 
• 195532-12-8 8-Cyano-1-cyclopropyl-7-((1S,6S)-2,8-diazabicyclo[4.3.0]nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid 
• 721970-37-2 N-methylmoxifloxacin 

Relevant articles and documents

Method for preparing moxifloxacin intermediate (S, S)-2, 8-diazabicyclo [4, 3, 0] nonane

The invention provides a method for preparing a moxifloxacin intermediate (S, S)-2, 8-diazabicyclo [4, 3, 0] nonane, and relates to the technical field of organic synthesis. According to the present invention, the 2-chloromethyl methyl nicotinate is subjected to asymmetric hydrogenation catalysis so as to obtain the intermediate with high chiral purity, chiral resolution is not required, and the moxifloxacin intermediate (S, S)-2, 8-diazabicyclo [4, 3, 0] nonane can be obtained through ammonolysis, reduction and cyclization. According to the method provided by the invention, chiral resolution is not needed, the process is simple, the process steps are short, the cost is low, and the product is high in chiral purity and high in total yield.

Method for preparing moxifloxacin intermediate (S, S)-2, 8-diazabicyclo [4, 3, 0] nonane

The invention provides a method for preparing a moxifloxacin intermediate (S, S)-2, 8-diazabicyclo [4, 3, 0] nonane, and relates to the technical field of organic synthesis. According to the method, the azaphthalide is used as a raw material, and due to the ring structure of the azaphthalide, the other two non-corresponding chiral isomers which are not needed in chiral reduction are almost not generated; the chiral purity of the intermediate obtained through reduction is very high, resolution is not needed, and (S, S)-2, 8-diazabicyclo [4, 3, 0] nonane can be obtained directly through ammonolysis, reduction, chlorination and cyclization subsequently. According to the method provided by the invention, chiral resolution is not needed, the process is simple, the process steps are short, the cost is low, and the product is high in chiral purity and high in total yield. Furthermore, in the subsequent product salifying and refining step, carboxylic acid with a chiral structure does not need to be used for salifying, and common achiral carboxylic acid can be used for refining, so the product purity is further improved.

Preparation method of moxifloxacin intermediate

The invention discloses a preparation method of a moxifloxacin intermediate. The invention provides a preparation method of a compound as shown in a formula III, which comprises the following step: ina solvent, in the presence of alkali, carrying out cyclization reaction as shown in the specification on a compound as shown in a formula II to obtain the compound as shown in the formula III. The method is simple to operate, high in chiral selectivity, simple in process, high in yield and high in purity.